New Funded Studies: Not Currently Recruiting


Principal Investigator: Sudeep Shivakumar

Funding: CIHR

Design: RCT evaluating extended VTE prophylaxis comparing rivaroxaban and aspirin to aspirin alone following total hip and knee arthroplasty

03. Muffin PTS

Principal Investigators: Jean-Philippe Galanaud, Susan Kahn

Funding: CIHR

Design: RCT evaluating venoactive medication vs placebo for reduction in PTS



Principal Investigators: Kerstin de Wit

Lana Castellucci and Marc Rodger (Ottawa)
Ali Mulla
Sudeep Shivakumar (Halifax)
Andrew Hirsch and Susan Kahn (Montreal)

Funding: CanVECTOR Pilot

Design: Prospective cohort study of patients on warfarin or DOAC for at least 3 months who require cessation of anticoagulation for a planned elective procedure.

05. Periop-3

Principal Investigator: Michael Kovacs

Design: Prospective observational cohort of patients on Warfarin or DOAC (Direct Oral Anticoagulant) for at least 3 months who require cessation of anticoagulation for a planned elective procedure.

06. Pilot PARTUM

Principal Investigator: Leslie Skeith, Marc Rodger


Design: Pilot RCT assessing the feasibility of an RCT evaluating aspirin in postpartum women at risk of developing VTE 

07. SAVER Trial

Principal Investigator: Aurélien Delluc, Marc Rodger

Funding: CIHR

Design: Placebo-controlled RCT of rosuvastatin to prevent recurrent VTE

09. RithMM

Principal Investigators: Martha Louzada

Funding: London Multiple Myeloma Support Group

Design: Pilot open-label RCT to compare the efficacy and safety of Rivaroxaban or ASA in preventing venous or arterial thromboembolic events in patients with myeloma on Len-Dex based therapy

For more information:NCT03428373

10. TILE Pilot study

Principal Investigators: Jean Philippe Galanaud, Susan Kahn;

Funding: LEO Pharma

Design: RCT comparing 3-weeks of tinzaparin then DOAC vs DOAC alone for prevention of PTS in high-risk symptomatic DVT patients (Iliac vein or common femoral vein).